RECRUITING

Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will investigate the effects of intermittent Theta Burst Stimulation (iTBS) on natural oscillatory frequency of the dorsolateral prefrontal cortex (DLPFC) and working memory in early-course schizophrenia (EC-SCZ). Transcranial magnetic stimulation (TMS) will be used to evoke oscillatory activity, and EEG will record the responses of EC-SCZ participants. A working memory task will also be incorporated in order to determine how DLPFC natural frequency (NF) is related to working memory performance. iTBS (active or sham) will be administered, then the oscillatory activity of DLPFC and working memory performance will be reassessed. The overarching goal is to determine whether iTBS can acutely enhance the oscillatory activity of the DLPFC and to evaluate the relationship between changes in the DLPFC and working memory performance.

Official Title

Enhancing Prefrontal Oscillatory Activity and Working Memory Performance With Noninvasive Brain Stimulation in Early-course Schizophrenia

Quick Facts

Study Start:2021-11-05

Study Completion:2026-08

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05102929

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 40 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT

Inclusion Criteria	Exclusion Criteria
1. ages 18-40 years 2. DSM diagnoses of Schizophrenia Spectrum Axis I disorders 3. a duration of less than three years from beginning of psychosis, defined by report of symptoms and/or history of treatment, based on clinical guidelines employed in our UPMC psychoses clinics in Pittsburgh.	1. DSM intellectual developmental disorder 2. significant head injury 3. medical illness affecting brain structure or function 4. significant neurologic disorder (e.g. seizure disorder) 5. personal history or family history of epilepsy 6. inability to provide informed consent 7. concussion with loss of consciousness (LOC) greater than 10 minutes 8. history of electroconvulsive therapy 9. diabetes with associated seizures, loss of sensation/weakness in arms or legs, or momentary LOC 10. pregnancy or postpartum (\<6 weeks after delivery or miscarriage), as determined by self-report 11. a psychotic illness with a temporal relation to substance use or head injury. 12. current or past co-morbidity for alcohol or psychoactive substance dependence 13. substance abuse, other than cannabis and/or alcohol, within the past one year

Inclusion Criteria

Exclusion Criteria

1. ages 18-40 years
2. DSM diagnoses of Schizophrenia Spectrum Axis I disorders
3. a duration of less than three years from beginning of psychosis, defined by report of symptoms and/or history of treatment, based on clinical guidelines employed in our UPMC psychoses clinics in Pittsburgh.

1. DSM intellectual developmental disorder
2. significant head injury
3. medical illness affecting brain structure or function
4. significant neurologic disorder (e.g. seizure disorder)
5. personal history or family history of epilepsy
6. inability to provide informed consent
7. concussion with loss of consciousness (LOC) greater than 10 minutes
8. history of electroconvulsive therapy
9. diabetes with associated seizures, loss of sensation/weakness in arms or legs, or momentary LOC
10. pregnancy or postpartum (\<6 weeks after delivery or miscarriage), as determined by self-report
11. a psychotic illness with a temporal relation to substance use or head injury.
12. current or past co-morbidity for alcohol or psychoactive substance dependence
13. substance abuse, other than cannabis and/or alcohol, within the past one year

Contacts and Locations

Study Contact

Sabine Janssen

CONTACT

412-246-6114

janssensa@upmc.edu

Principal Investigator

Fabio Ferrarelli, MD, PhD

PRINCIPAL_INVESTIGATOR

University of Pittsbrugh

Study Locations (Sites)

University of Pittsburgh

Pittsburgh, Pennsylvania, 15213

United States

Collaborators and Investigators

Sponsor: Fabio Ferrarelli

Fabio Ferrarelli, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Pittsbrugh

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-11-05

Study Completion Date2026-08

Study Record Updates

Study Start Date2021-11-05

Study Completion Date2026-08

Terms related to this study

Additional Relevant MeSH Terms

Schizophrenia